Karahalil Bensu, Yağar Seyhan, Ozin Yasemin
Gazi University, Faculty of Pharmacy, Department of Toxicology, 06330, Hipodrom Ankara, Turkey.
Curr Drug Saf. 2007 Jan;2(1):43-6. doi: 10.2174/157488607779315426.
Helicobacter pylori (H. pylori) is a gram negative, spiral, microaerophylic bacterium that infects the stomach of more than 50% of the human population worldwide. H. pylori is well recognized as a critical factor in the majority of patients with peptic ulcer disease and successful treatment results in cure of the disease. On the other hand, H. pylori infection has been associated with several extra-intestinal diseases such as hepatic encephalopathy. In this study, a triple treatment was used in management and eradication of H. pylori infection. We hypothesized that H. pylori infection and/or eradication treatment increased the releasing of alpha-glutathione S-transferase (alpha-GST). We also investigated whether alpha-GST is a more sensitive marker than aminotransferases (traditional liver function tests) for hepatocellular damage. However, we did not find any association between both H. pylori infection and eradication treatment and alpha-GST levels. According to our data, eradication treatment did not cause hepatocellular damage.
幽门螺杆菌(H. pylori)是一种革兰氏阴性、螺旋形、微需氧菌,全球超过50%的人口胃部都受到其感染。幽门螺杆菌被公认为是大多数消化性溃疡病患者的关键因素,成功治疗可治愈该疾病。另一方面,幽门螺杆菌感染与几种肠道外疾病有关,如肝性脑病。在本研究中,采用三联疗法来管理和根除幽门螺杆菌感染。我们假设幽门螺杆菌感染和/或根除治疗会增加α-谷胱甘肽S-转移酶(α-GST)的释放。我们还研究了α-GST对于肝细胞损伤是否是比转氨酶(传统肝功能测试)更敏感的标志物。然而,我们未发现幽门螺杆菌感染和根除治疗与α-GST水平之间存在任何关联。根据我们的数据,根除治疗不会导致肝细胞损伤。